These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33658967)

  • 1. Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials.
    Turalde CWR; Espiritu AI; Anlacan VMM
    Front Neurol; 2020; 11():574748. PubMed ID: 33658967
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
    J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment for memory disorder in multiple sclerosis.
    He D; Zhang Y; Dong S; Wang D; Gao X; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008876. PubMed ID: 24343792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial.
    Falsafi Z; Tafakhori A; Agah E; Mojarrad M; Dehghani R; Ghaffarpour M; Aghamollaii V; Mousavi SV; Fouladi Z; Pourghaz B; Balali P; Harirchian MH
    J Neurol Sci; 2020 Jul; 414():116844. PubMed ID: 32335343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment for memory disorder in multiple sclerosis.
    He D; Zhou H; Guo D; Hao Z; Wu B
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008876. PubMed ID: 21975787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine induces reversible neurologic impairment in patients with MS.
    Villoslada P; Arrondo G; Sepulcre J; Alegre M; Artieda J
    Neurology; 2009 May; 72(19):1630-3. PubMed ID: 19092106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amantadine for fatigue in multiple sclerosis.
    Taus C; Giuliani G; Pucci E; D'Amico R; Solari A
    Cochrane Database Syst Rev; 2003; (2):CD002818. PubMed ID: 12804439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non pharmacological interventions for spasticity in multiple sclerosis.
    Amatya B; Khan F; La Mantia L; Demetrios M; Wade DT
    Cochrane Database Syst Rev; 2013 Feb; (2):CD009974. PubMed ID: 23450612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Information provision for people with multiple sclerosis.
    Köpke S; Solari A; Khan F; Heesen C; Giordano A
    Cochrane Database Syst Rev; 2014 Apr; (4):CD008757. PubMed ID: 24752330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
    Buckley JS; Salpeter SR
    Drugs Aging; 2015 Jun; 32(6):453-67. PubMed ID: 25941104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of exercise training in adults with multiple sclerosis with severe mobility disability: A systematic review and future research directions.
    Edwards T; Pilutti LA
    Mult Scler Relat Disord; 2017 Aug; 16():31-39. PubMed ID: 28755682
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.